|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 3.730 USD | -4.85% |
|
-13.05% | -67.98% |
| 08-13 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-13 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SPRY | Delayed | |
CBOE
| SPRY | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 4.08 | 6.38 | 7.23 |
| Spread/Res. | -8.58% | -41.54% | -48.41% |
| Spread/Supp. | +3.61% | +10.36% | +48.66% |
| Support | 3.6 | 3.38 | 2.509 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- SPRY Stock
- Charts ARS Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
